This page shows the latest Viking Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Nevertheless, William Blair thinks the setback could prompt Gilead to seek out other licensing candidates to expand it liver disease pipeline, and they think one possible candidate could be Viking
cutting a deal to acquire US start-up Jecure Therapeutics. ... Other competition is coming from pharma heavyweights Novartis and Pfizer, which recently joined forces to test three drugs in combination, and other clinical-stage player such as Allergan,
Impressive data in a phase 2 trial caused shares in Viking Therapeutics to almost double yesterday as investors got excited about another candidate for non-alcoholic steatohepatitis (NASH). ... Viking’s VK2809 – a thyroid hormone receptor beta
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
The acquisition for up to $658m (a 59 per cent premium on the pre-bid share price) of the US company, Chelsea Therapeutics, achieves both those goals. ... As a footnote, Ligand this month licensed to what appears to be a new company called Viking
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...